FindTrial
Sign In

Carboplatin-Paclitaxel

DRUG2 trials

Sponsors

Tesaro, Inc., ARCAGY/ GINECO GROUP

Conditions

Advanced CancerEndometrial CancerMetastatic CancerNeoplasmsNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon Small Cell Lung Cancer Stage IIIBSolid Tumor

Phase 1

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
CompletedNCT03307785
Tesaro, Inc.Advanced Cancer, Metastatic Cancer, Neoplasms +4
Start: 2017-10-12End: 2024-12-11Updated: 2025-11-25

Phase 3

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
Active, not recruitingNCT05201547
ARCAGY/ GINECO GROUPEndometrial Cancer
Start: 2022-04-15End: 2029-10-31Target: 260Updated: 2025-12-04

Related Papers

DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients
Future Oncology2025-05-05
Real-world patient characteristics and survival outcomes in patients with advanced or recurrent endometrial cancer in England: a retrospective, population-based study
BMJ Open2024-11-011 citations
Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).
Journal of Clinical Oncology2023-06-0120 citations
Dostarlimab: A Review.
2022-07-2639 citations
Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours
British Journal of Clinical Pharmacology2022-03-3125 citations
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
Journal for ImmunoTherapy of Cancer2022-03-0116 citations
IOLite: Multipart, phase 1b, dose-finding study of the PD-1 inhibitor dostarlimab in combination with the PARP inhibitor niraparib ± bevacizumab (bev), or with platinum-based chemotherapy ± bev for advanced cancer.
Journal of Clinical Oncology2019-05-2010 citations